US EditionPublished • loading... • Updated
Kenai doses first patient in Phase I trial of cell therapy for Parkinson’s
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Kenai doses first patient in Phase I trial of cell therapy for Parkinson’s
Kenai Therapeutics has dosed the first patient in its Phase I REPLACE trial evaluating RNDP-001 for moderate to moderate-severe idiopathic Parkinson’s.The post Kenai doses first patient in Phase I trial of cell therapy for Parkinson’s appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
